| Literature DB >> 26301114 |
Mehdi Goudarzi1, Mehdi Azad2, Sima Sadat Seyedjavadi3.
Abstract
Objective. Plasmid-mediated quinolone resistance (PMQR) plays an important role in the development of clinical resistance to quinolone. The aim of this study was to investigate PMQR determinants among extended-spectrum β-lactamases- (ESBL-) producing Klebsiella pneumoniae recovered from patients with nosocomial urinary tract infection (UTI). Methods. A total of 247 ESBL-producing K. pneumoniae isolates were collected from 750 patients with UTI. ESBL production was confirmed by double disc synergy test and combined disc diffusion test. The prevalence of PMQR determinants among ESBL-producing K. pneumoniae was assessed using PCR method. Results. The rates of resistance to antimicrobial agents in present study varied from 14.2% to 98.8%. In comparison with other PMQR genotypes, the frequency of aac(6')-Ib (68.8%) was strikingly high. Of the 247 isolates tested, qnrA, qnrB, qnrS, and qepA genes were present in 3.6%, 1.6%, 1.2, and 2%, respectively. oqxA and oqxB were detected in 56.7% and 54.6% of isolates. The predominant coexisting ESBL and PMQR profile among our isolates included bla CTX-M and aac(6')-Ib, oqxA, oqxB (28.3%) and bla TEM, bla SHV and aac(6')-Ib, oqxA, and oqxB (19.4%) profile. Conclusion. Given the linkage observed between resistance to quinolones and beta lactam antibiotics, therapeutic protocol with fluoroquinolones and beta lactam antibiotics should be seriously revised in Tehran hospitals.Entities:
Year: 2015 PMID: 26301114 PMCID: PMC4537771 DOI: 10.1155/2015/518167
Source DB: PubMed Journal: Scientifica (Cairo) ISSN: 2090-908X
Primers sequence used to detect bla genes and PMQR genes in this study.
| Target gene | Nucleotide sequence | Size of the amplified product (bp) | Reference |
|---|---|---|---|
|
| 5′-TCGGGGAAATGTGCGCG-3′ | 972 |
[ |
| 5′-TGCTTAATCAGTGAGGCACC-3′ | |||
|
| |||
|
| 5′-GGGTTATTCTTATTTGTCGC-3′ | 615 |
[ |
| 5′-TTAGCGTTGCCAGTGCTC-3′ | |||
|
| |||
|
| 5′-ACGCTGTTGTTAGGAAGTG-3′ | 857 |
[ |
| 5′-TTGAGGCTGGGTGAAGT-3′ | |||
|
| |||
|
| 5′-TTGCGATGCTCTATGAGTGGCTA-3′ | 482 |
[ |
| 5′-CTCGAATGCCTGGCGTGTTT-3′ | |||
|
| |||
|
| 5′-CTGCAGGTACTGCGTCATG-3′ | 403 |
[ |
| 5′-CGTGTTGCTGGAGTTCTTC-3′ | |||
|
| |||
|
| 5′-GACAGCGTCGCACAGAATG-3′ | 339 |
[ |
| 5′-GGAGACGAGGTTGGTATGGA-3′ | |||
|
| |||
|
| 5′-CGAAGAAAGACCTCCCTACCC-3′ | 240 |
[ |
| 5′-CGCCGCCAATGAGATACA-3′ | |||
|
| |||
|
| 5′-AGAGGATTTCTCACGCCAGG-3′ | 619 |
[ |
| 5′-GCAGCACTATKACTCCCAAGG-3′ | |||
|
| |||
|
| 5′-GATCGTGAAAGCCAGAAAGG-3′ | 469 |
[ |
| 5′-CGATGCCTGGTAGTTGTCC-3′ | |||
|
| |||
|
| 5′-GCAAGTTCATTGAACAGGCT-3′ | 428 |
[ |
| 5′-TCTAAACCGTCGAGTTCGGCG-3′ | |||
Antimicrobial susceptibly pattern of 247 ESBL producing K. pneumoniae isolated from patients with UTI to 15 antimicrobial agents.
| Antibiotics | Antibiotic susceptibility ( | ||
|---|---|---|---|
| R | I | S | |
|
|
|
| |
| Cefotaxime | 197 (79.7) | 5 (2.1) | 45 (18.2) |
| Ceftazidime | 201 (81.4) | 10 (4) | 36 (14.6) |
| Ceftriaxone | 160 (64.8) | 4 (1.6) | 83 (33.6) |
| Cefpodoxime | 188 (76.2) | 7 (2.8) | 52 (21) |
| Piperacillin | 160 (64.8) | 0 (0) | 87 (35.2) |
| Aztreonam | 168 (68) | 0 (0) | 79 (32) |
| Imipenem | 93 (37.7) | 4 (1.6) | 150 (60.7) |
| Amikacin | 86 (34.8) | 6 (2.4) | 155 (62.8) |
| Gentamicin | 143 (57.9) | 15 (6.1) | 89 (36) |
| Norfloxacin | 199 (80.5) | 4 (1.6) | 44 (17.9) |
| Ciprofloxacin | 150 (60.8) | 6 (2.4) | 91 (36.8) |
| Nalidixic acid | 155 (62.8) | 12 (4.8) | 80 (32.4) |
| Cotrimoxazole | 178 (72.1) | 5 (2) | 64 (25.9) |
| Tetracycline | 120 (48.6) | 8 (3.2) | 119 (48.2) |
| Tigecycline | 35 (14.2) | 0 (0) | 212 (85.8) |
Distribution of ESBL-encoding genes and PMQR genes among 247 ESBL producers.
| Resistance genes | Number (%) |
|---|---|
|
| 185 (74.9) |
|
| 173 (70) |
|
| 170 (68.8) |
|
| 148 (59.9) |
|
| 140 (56.7) |
|
| 130 (54.6) |
|
| 9 (3.6) |
|
| 5 (2) |
|
| 4 (1.6) |
|
| 3 (1.2) |
Coexisting ESBL and PMQR resistance genes among 247 ESBL producers.
| Coexisting resistance genes | Number (%) |
|---|---|
|
| 85 (34.4) |
|
| 70 (28.3) |
|
| 48 (19.4) |
|
| 24 (9.7) |
|
| 7 (2.8) |
|
| 4 (1.6) |
|
| 2 (0.8) |
|
| 1 (0.4) |